Newtown biopharm firm could reap $50M from Chinese licensing deal

Onconova Therapeutics Inc. could receive more than $50 million under a licensing deal it signed Monday for its lead experimental cancer therapy. HanX Biopharmaceuticals acquired the rights in Greater China to rigosertib, a new drug candidate Bucks County-based Onconova is developing initially as a treatment for patients at higher risks for developing myelodysplastic syndromes of MDA. MDS is a type of cancer that can occur when the blood-fo rming cells in bone marrow become abnormal. Under the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news